Objective: To determine the effect of new, persistent or reverted ischaemic ECG abnormalities at ages 50 and 70 years on the risk of subsequent cardiovascular disease.
Design, setting and participants: A prospective community-based observational cohort of 50-year-old men in Sweden, followed for 32 years. 2322 men of age 50 years participated in 1970–3, and 1221 subjects were re-examined at the age of 70 years.
Main outcome measures: Myocardial infarction (MI), cardiovascular mortality and overall mortality.
Results: At 50 years of age, after adjusting for established conventional risk factors, T wave abnormalities, ST segment depression, major Q/QS pattern and ECG-left ventricular hypertrophy were all found to be independent risk factors for the main outcome measures during the 32 years of follow-up. When ECG variables were re-measured at 70 years of age, they were still found to be independent risk factors for the mortality outcomes, but lost in significance for prediction of MI. Regarding mortality, it was twice as dangerous to have persistent T wave abnormalities (HR 4.63; 95% CI 2.18 to 9.83) or ST segment depression (HR 5.66; 95% CI 1.77 to 18.1), as with new T wave abnormalities (HR 2.20; 95% CI 1.48 to 3.29) or ST segment depression (HR 2.55; 95% CI 1.74 to 3.75), developing between ages 50 and 70 years. The addition of “ECG indicating ischaemia” significantly increased the predictive power of the Framingham score (p<0.001).
Conclusions: It is worthwhile to obtain serial ECGs for proper risk assessment, since persistent ST-T abnormalities carried twice as high a risk for future mortality compared with new or reverted abnormalities.
- CVD, cardiovascular disease
- LBBB, left bundle branch block
- LVH, left ventricular hypertrophy
- MC, Minnesota Code
- MI, myocardial infarction
- ROC, receiver-operating characteristics
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Published Online First 3 May 2007
Competing interests: AstraZeneca R&D, Sweden, also employs CSM and LL. AstraZeneca R&D, Sweden, had no role in the study design; in the collection, analysis and interpretation of data; in the writing of the manuscript; nor in the decision to submit the manuscript for publication.
None of the sponsors had any role in the study design: in the collection, analysis and interpretation of data; in the writing of the manuscript; nor in the decision to submit the manuscript for publication.
CSM, BZ, JS and LL were involved in study concept and design. Analysis of the data was performed by CSM, whereas CSM, JS LL and BZ interpreted the data. CSM was involved in the drafting of the manuscript and critical revision of the manuscript for important intellectual content was done by CSM, BZ and LL.